Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Arthritis, Rheumatoid 6Neoplasms 3Graft vs Host Disease 2Myelodysplastic Syndromes 1Leukemia 1Hematologic Neoplasms 1Arthritis 1Anemia, Refractory 1

Interventions

Tacrolimus 37Methotrexate 27Cyclophosphamide 27Mycophenolic Acid 21fludarabine phosphate 19Busulfan 19Antilymphocyte Serum 19Cyclosporine 18Sirolimus 16Methylprednisolone 16fludarabine 15Peripheral Blood Stem Cell Transplantation 15Melphalan 14Filgrastim 13Radiotherapy 12Whole-Body Irradiation 8Granulocyte Colony-Stimulating Factor 8thymoglobulin 6Stem Cell Transplantation 6Rituximab 6Prednisone 6Pentostatin 6Hematopoietic Stem Cell Transplantation 5Etoposide 5ruxolitinib 4Thiotepa 4Flow Cytometry 4Cytarabine 4Cyclosporins 4Cord Blood Stem Cell Transplantation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Graft vs Host Disease × Abatacept × Clear all
NCT01743131 2025-12-11

Abatacept as GVHD Prophylaxis Phase 2

Boston Children's Hospital

Phase 2 Completed
186 enrolled 14 charts 1 FDA

Graft vs Host Disease, Neoplasms

NCT03680092 2025-10-02

Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation

University of California, San Diego

Phase 2 Completed
43 enrolled 10 charts
Other hematologic neoplasm

Graft vs Host Disease, Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡